THECOMPOUND

Search

Search guides, news, and programs

Compare
Home / News / Wegovy for Kids 6 to 11: STEP Young

The Compound · News

Wegovy for kids 6 to 11: what the STEP Young trial found

Wegovy (semaglutide) cut BMI by 13.5% in children aged 6 to under 12 with obesity over 68 weeks, while BMI rose 2.7% on placebo. The full STEP Young results were published in the New England Journal of Medicine on November 16 and presented at ObesityWeek 2026. It is the first phase 3 semaglutide trial in children this young. No GLP-1 drug is approved for them yet.

The CompoundNovember 17, 20266 min read

The gist

  • STEP Young (167 children aged 6 to under 12, mostly with severe obesity): BMI fell 13.5% on semaglutide versus a 2.7% rise on placebo at 68 weeks. Novo’s 17.4% figure is the on-treatment estimate.
  • About 38% of treated children ended below the obesity cutoff, versus 2% on placebo. Almost 80% moved down at least one BMI category.
  • Side effects were mostly GI and clustered during dose increases. 4% quit for side effects. No growth or puberty concerns were reported.
  • Wegovy is approved only for ages 12 and up. Novo has not said when it will file for younger children.

What STEP Young found

Novo Nordisk randomized 167 children aged 6 to under 12 in a multinational, double-blind trial. Two thirds got weekly semaglutide (112 children) and one third got placebo (55). Every family also got diet and activity support. These were not borderline cases. More than 85% of the kids started with class II or class III obesity, and CNBC reports nearly half already had a related condition such as high blood pressure, high cholesterol, or sleep apnea.

Dosing was by body weight. Children over 60 kg could go up to 2.4 mg, the adult Wegovy dose. Children between 45 and 60 kg topped out at 1.7 mg. Anyone who could not tolerate those stayed at the highest dose they could handle. Treatment ran 104 weeks, then stopped for a 7-week safety washout. The primary result was measured at week 68.

−13.5%BMI change on semaglutide at 68 weeks, everyone randomized
+2.7%BMI change on placebo over the same period
~38%Children on semaglutide who ended below the obesity cutoff, versus 2% on placebo
79%Moved down at least one BMI category, versus 23% on placebo

Why BMI and not pounds? Kids are still growing. A child who holds the same weight while getting taller is improving, so pediatric trials track BMI relative to age and sex. That is also why the placebo group's BMI rose. Untreated childhood obesity tends to get worse, not stay put.

Wegovy for kids: 13.5% or 17.4%?

Novo's press release leads with a 17.4% BMI drop. The NEJM paper leads with 13.5%. Same trial, different math.

The 13.5% counts every child who was randomized, including the ones who stopped. That is the primary result. The 17.4% estimates what would happen if everyone stayed on the drug the whole time. The headline "almost 80% got a 10% BMI reduction" is also the on-treatment version, and it was a supportive endpoint, not the main one. For a parent, 13.5% is the safer number to anchor on.

OutcomeSemaglutidePlacebo
BMI change at week 68, everyone randomized−13.5%+2.7%
BMI change at week 68, stayed on treatment−17.4%+2.2%
BMI down 10% or more at week 6874.7%4.3%
BMI change at week 104, everyone randomized−9.4%+8.4%
No longer in the obesity range at week 10433.3%2.4%
Stopped due to side effects4%2%

What happened between week 68 and week 104

This part gets less attention, and it should get more. Between week 68 and week 104, the semaglutide group's BMI drifted back up, from −13.5% to −9.4% on the everyone-counted measure. Even on the on-treatment estimate it slipped from −17.4% to −14.0%. The share no longer in the obesity range fell from about 38% to 33%.

The gap versus placebo held, at roughly 18 points, because the placebo group kept climbing. So the drug kept working relative to doing nothing. But it did not keep pushing BMI down. Novo also notes the week 104 numbers were not adjusted for multiple comparisons, so treat them as a signal. Adults show a similar plateau. In children it raises a harder question: what does maintenance look like when treatment might start at age 7?

Side effects in young children

Adverse events showed up in 96% of the semaglutide group and 93% of the placebo group. That sounds alarming until you remember it is two years of tracking every cold and scraped knee in 167 kids. The useful comparison is the gap. GI effects like nausea, vomiting, and diarrhea were the most common and happened more often on semaglutide, mostly during dose increases.

Only 4% stopped semaglutide for side effects, versus 2% on placebo. That is lower than the 9.3% dropout seen with tirzepatide in teens. Serious adverse events were 9% in both arms. Psychiatric adverse events were 21% on semaglutide and 24% on placebo, so no excess there. Novo reported no concerns for growth or puberty. The standard Wegovy boxed warning for thyroid C-cell tumors still applies.

How STEP Young compares with the teen trials

In STEP TEENS, the 2022 trial behind Wegovy's approval for ages 12 and up, semaglutide cut BMI by 16.1% versus a 0.6% rise on placebo over 68 weeks. STEP Young lands at a similar gap, about 16 points, in much younger and heavier children. The newly published SURMOUNT-ADOLESCENTS trial found tirzepatide cut BMI 18.5% in 12 to 17 year olds. No trial has compared the two drugs head to head in kids, and the populations differ, so do not read too much into a two-point spread.

Is Wegovy approved for kids under 12?

Current status, November 17, 2026

  • Wegovy is FDA approved for obesity in people aged 12 and older
  • Semaglutide is not approved for children under 12 in the US
  • Novo Nordisk has not announced an FDA filing date for this age group
  • Lilly is running its own tirzepatide trial in children aged 6 to under 12

Off-label prescribing is legal, but for a 7 or 9 year old it would be rare, and insurers almost never pay for off-label pediatric use. The open questions are the big ones. How long does a child stay on it? What happens when they stop? Adult data says most weight comes back, which our guide to preventing GLP-1 weight rebound covers. Cost matters too when treatment could run for years. For adults, see what semaglutide costs online and our GLP-1 cost comparison.

Frequently Asked Questions

Get the 2026 GLP-1 Cost & Eligibility Cheat Sheet

One page: real monthly costs for compounded vs brand semaglutide and tirzepatide, the BMI thresholds that qualify you, and the five questions to ask before you pay. We'll email it now.

No spam. Unsubscribe anytime.

Medical Disclaimer: This page is for informational purposes only and does not constitute medical advice. Peptides and GLP-1 medications require a prescription and should only be taken under the supervision of a licensed healthcare provider. Individual results vary. Always consult a doctor before starting any new medication or compound.

Sources

  1. NEJM: Semaglutide for the Treatment of Obesity in Children 6 to <12 Years of Age (STEP Young, published November 16, 2026)
  2. Novo Nordisk: Wegovy resulted in a BMI reduction of 10% or more in almost 80% of children with obesity aged 6 to under 12 (November 16, 2026)
  3. CNBC: Novo says Wegovy injection lowers BMI and obesity rates in children in trial (November 16, 2026)
  4. Contemporary Pediatrics: Semaglutide cuts BMI 13.5% in children aged 6 to 11 with obesity
  5. ClinicalTrials.gov: STEP Young, semaglutide in children with obesity aged 6 to under 12 (NCT05726227)
  6. Weghuber et al. Once-Weekly Semaglutide in Adolescents with Obesity (STEP TEENS), N Engl J Med 2022
The Compound app

The Compound app

Track your protocol, read the research, and stay on top of what's new in GLP-1s and peptides.

Download